<DOC>
	<DOCNO>NCT00338247</DOCNO>
	<brief_summary>This study provide pre-approval drug access lapatinib , combination capecitabine , patient whose breast cancer progress therapy</brief_summary>
	<brief_title>EAP ( Expanded Access Protocol ) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Inclusion criterion : May receive prior lapatinib another trial . Previous capecitabine ( previous agent nonlapatinib contain regimen ) also permit . Prior treatment hormonal therapy allow . Must advance metastatic breast cancer progression ( assess modify RECIST ) prior therapy , must include following : prior treatment anthracycline , taxane , trastuzumab alone combination therapy . Trastuzumab must administer adjuvant , locally advanced metastatic setting . Must tumor overexpress ErbB2 define +3 IHC FISH positive ErbB2 gene amplification . The status ErbB2 expression must document prior study entry . Must &gt; /= 18 year age Life expectancy &gt; 8 week Must recover side effect previous treatment Patients CNS mets eligible provide treatment prohibit medication list protocol require Cardiac ejection fraction must within institutional range normal measure ECHO . MUGA scan allow ECHOs perform Able swallow retain oral medication Must adequate hematologic , hepatic renal function Exclusion criterion : Pregnant lactating female Malabsorption syndrome , disease significantly affect GI function , resection stomach bowel , ulcerative colitis Concurrent disease condition would make patient inappropriate study participation Unresolved unstable toxicity prior administration another investigational drug and/or prior cancer treatment Uncontrolled infection Active cardiac disease define history uncontrolled symptomatic angina ; history arrhythmia require medication , clinically significant , exception asymptomatic atrial fibrillation require anticoagulation ; MI &lt; 6 month study entry ; uncontrolled symptomatic CHF ; ejection fraction institutional normal limit ; cardiac condition would make protocol unreasonably hazardous patient Receiving concurrent chemotherapy ( capecitabine ) , radiation therapy , immunotherapy , biologic therapy hormonal therapy cancer . Concurrent therapy bisphosphonates allow History allergic reaction attribute compound similar composition lapatinib excipients History allergic reaction attribute compound similar chemical composition capecitabine , fluorouracil excipients Known DPD deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>advanced</keyword>
	<keyword>TYKERB</keyword>
	<keyword>HER2 positive</keyword>
	<keyword>Stage IIIc</keyword>
	<keyword>ErbB2 positive</keyword>
	<keyword>GW572016</keyword>
	<keyword>metastatic</keyword>
	<keyword>Stage IIIb</keyword>
	<keyword>breast cancer</keyword>
</DOC>